Cybin Inc. Common Stock
HELP
Rank in Stocks
#11654
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Share Price
$10.30
Last synced: 2026-08-11
Market Cap
$638.32M
Change (1 day)
2.88%
Change (1 year)
9,119.52%
Country
CA
Trade Cybin Inc. Common Stock (HELP)
Category
Healthcare
P/B ratio for Cybin Inc. Common Stock (HELP)
P/B ratio as of 2026 TTM: 0
According to Cybin Inc. Common Stock latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Cybin Inc. Common Stock from 2026 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
